# SCN5A

## Overview
The SCN5A gene encodes the sodium voltage-gated channel alpha subunit 5, known as NaV1.5, which is a critical transmembrane protein predominantly expressed in cardiac tissue. NaV1.5 plays a vital role in the cardiac action potential by facilitating the rapid influx of sodium ions during the depolarization phase, thereby ensuring the proper initiation and propagation of electrical impulses in the heart (Rook2011Biology; Abriel2010Cardiac). Structurally, NaV1.5 is composed of four homologous domains, each containing six transmembrane segments, and functions as a monomer that can associate with auxiliary β-subunits to form a functional channel complex (Dong2020Life; Veerman2015The). The gene is subject to alternative splicing, resulting in various isoforms that may have distinct functional properties (Schroeter2010Structure). Mutations in SCN5A are associated with several cardiac disorders, including Brugada syndrome and Long QT syndrome, highlighting its clinical significance in cardiac electrophysiology and arrhythmogenesis (Brlek2023Case; Verkerk2018Disease).

## Structure
The SCN5A gene encodes the NaV1.5 protein, a critical component of the cardiac sodium channel. This protein is a large transmembrane structure with a molecular weight of approximately 220 kDa, consisting of 2015 or 2016 amino acids, depending on the splice variant (Abriel2010Cardiac). The primary structure of NaV1.5 includes four homologous domains (DI-DIV), each containing six transmembrane segments (S1-S6) (Veerman2015The). The S4 segments are positively charged and function as voltage sensors, while the S5 and S6 segments, along with the P loops, form the channel's pore (Schroeter2010Structure; Dong2020Life).

The tertiary structure involves the folding of these domains into a three-dimensional shape, facilitating the channel's function in cardiac action potentials. NaV1.5 operates as a monomer but is often associated with auxiliary β-subunits, forming a quaternary structure that modulates its biophysical properties and membrane localization (Dong2020Life; Abriel2010Cardiac).

Post-translational modifications such as glycosylation, phosphorylation, and ubiquitylation are crucial for NaV1.5's function and localization. Glycosylation is essential for membrane localization, while phosphorylation and ubiquitylation regulate channel activity and degradation (Dong2020Life; Abriel2010Cardiac). The SCN5A gene undergoes alternative splicing, resulting in several NaV1.5 splice variants with distinct properties, such as NaV1.5c and NaV1.5d, which have implications for cardiac function and disease (Schroeter2010Structure).

## Function
The SCN5A gene encodes the alpha subunit of the cardiac sodium channel Na v 1.5, which is essential for the proper electrical activity of the heart. This channel facilitates the rapid influx of sodium ions during the depolarization phase of the cardiac action potential, a critical step for the initiation and propagation of action potentials in cardiac cells (Rook2011Biology; Abriel2010Cardiac). Na v 1.5 is primarily active in the cell membrane of cardiac myocytes, where it contributes to the fast upstroke of the cardiac action potential, enabling rapid impulse propagation through cardiac tissue (Veerman2015The).

The channel is composed of four homologous domains, each containing six transmembrane segments, with the S4 segment acting as a voltage sensor and the S5 and S6 segments forming the pore that determines ion selectivity (Dong2020Life). Na v 1.5's function is regulated by its gating properties, which are voltage and time-dependent, allowing it to open or close in response to changes in membrane potential (Veerman2015The). The proper function of Na v 1.5 is crucial for maintaining normal cardiac rhythm and function, as it ensures effective cardiac muscle contraction and overall heart function (Abriel2010Cardiac).

## Clinical Significance
Mutations in the SCN5A gene, which encodes the cardiac sodium channel NaV1.5, are linked to a variety of cardiac conditions. Brugada syndrome (BrS) is associated with loss-of-function mutations in SCN5A, leading to reduced sodium current (I Na) and increased risk of ventricular arrhythmias and sudden cardiac death (Brlek2023Case; Verkerk2018Disease). Long QT syndrome type 3 (LQT3) results from gain-of-function mutations, causing prolonged cardiac action potentials and heightened risk of arrhythmias (Wang1995SCN5A; Veerman2015The). 

SCN5A mutations are also implicated in atrial fibrillation (AF), which can arise from both gain- and loss-of-function mutations, affecting the heart's electrical activity (Li2018SCN5A). Progressive cardiac conduction defect (PCCD) and sick sinus syndrome (SSS) are linked to SCN5A mutations, with overlapping features with BrS and LQT3 (Verkerk2018Disease). 

Dilated cardiomyopathy (DCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC) are structural heart diseases associated with SCN5A mutations, though the mechanisms are not fully understood (Verkerk2018Disease). These mutations can lead to a spectrum of arrhythmogenic syndromes, often inherited as an autosomal dominant trait with incomplete penetrance (Brlek2023Case).

## Interactions
The SCN5A gene encodes the Nav1.5 sodium channel, which is involved in various protein interactions crucial for its regulation and function. Nav1.5 interacts with ankyrin-G, which is essential for its localization in cardiac cells (Shao2009Protein–protein). Syntrophins and dystrophin form a multiprotein complex with Nav1.5, stabilizing it at the plasma membrane and affecting its expression and function (Gavillet2006Cardiac; Shao2009Protein–protein). The channel also interacts with calmodulin, which binds to its IQ motif, influencing its voltage dependence and stability (Abriel2010Cardiac).

Nav1.5 is subject to regulation by ubiquitylation through Nedd4-like enzymes, which mediate its internalization and stability (Abriel2010Cardiac). The 14-3-3 protein family interacts with Nav1.5, modifying its biophysical properties without affecting its trafficking (Abriel2010Cardiac). MOG1, encoded by the RANGRF gene, acts as a co-factor for Nav1.5's optimal expression at the cell membrane (Abriel2010Cardiac).

Mutations in SCN5A can disrupt these interactions, leading to cardiac conditions such as Long QT Syndrome and Brugada Syndrome (Abriel2010Cardiac). These interactions highlight the complex regulatory network involving Nav1.5 and its role in cardiac electrophysiology.


## References


[1. (Wang1995SCN5A) Qing Wang, Jiaxiang Shen, Igor Splawski, Donald Atkinson, Zhizhong Li, Jennifer L Robinson, Arthur J Moss, Jeffrey A Towbin, and Mark T Keating. Scn5a mutations associated with an inherited cardiac arrhythmia, long qt syndrome. Cell, 80(5):805–811, March 1995. URL: http://dx.doi.org/10.1016/0092-8674(95)90359-3, doi:10.1016/0092-8674(95)90359-3. This article has 1283 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/0092-8674(95)90359-3)

[2. (Schroeter2010Structure) Annett Schroeter, Stefan Walzik, Steve Blechschmidt, Volker Haufe, Klaus Benndorf, and Thomas Zimmer. Structure and function of splice variants of the cardiac voltage-gated sodium channel nav1.5. Journal of Molecular and Cellular Cardiology, 49(1):16–24, July 2010. URL: http://dx.doi.org/10.1016/j.yjmcc.2010.04.004, doi:10.1016/j.yjmcc.2010.04.004. This article has 60 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.yjmcc.2010.04.004)

[3. (Rook2011Biology) M. B. Rook, M. M. Evers, M. A. Vos, and M. F. A. Bierhuizen. Biology of cardiac sodium channel nav1.5 expression. Cardiovascular Research, 93(1):12–23, September 2011. URL: http://dx.doi.org/10.1093/cvr/cvr252, doi:10.1093/cvr/cvr252. This article has 166 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/cvr/cvr252)

[4. (Dong2020Life) Caijuan Dong, Ya Wang, Aiqun Ma, and Tingzhong Wang. Life cycle of the cardiac voltage-gated sodium channel nav1.5. Frontiers in Physiology, December 2020. URL: http://dx.doi.org/10.3389/fphys.2020.609733, doi:10.3389/fphys.2020.609733. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2020.609733)

[5. (Abriel2010Cardiac) Hugues Abriel. Cardiac sodium channel nav1.5 and interacting proteins: physiology and pathophysiology. Journal of Molecular and Cellular Cardiology, 48(1):2–11, January 2010. URL: http://dx.doi.org/10.1016/j.yjmcc.2009.08.025, doi:10.1016/j.yjmcc.2009.08.025. This article has 309 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.yjmcc.2009.08.025)

[6. (Gavillet2006Cardiac) Bruno Gavillet, Jean-Sébastien Rougier, Andrea A. Domenighetti, Romina Behar, Christophe Boixel, Patrick Ruchat, Hans-Anton Lehr, Thierry Pedrazzini, and Hugues Abriel. Cardiac sodium channel na v 1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin. Circulation Research, 99(4):407–414, August 2006. URL: http://dx.doi.org/10.1161/01.res.0000237466.13252.5e, doi:10.1161/01.res.0000237466.13252.5e. This article has 202 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1161/01.res.0000237466.13252.5e)

[7. (Li2018SCN5A) Wenjia Li, Lei Yin, Cheng Shen, Kai Hu, Junbo Ge, and Aijun Sun. Scn5a variants: association with cardiac disorders. Frontiers in Physiology, October 2018. URL: http://dx.doi.org/10.3389/fphys.2018.01372, doi:10.3389/fphys.2018.01372. This article has 101 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2018.01372)

[8. (Shao2009Protein–protein) Dongmin Shao, Kenji Okuse, and Mustafa B.A. Djamgoz. Protein–protein interactions involving voltage-gated sodium channels: post-translational regulation, intracellular trafficking and functional expression. The International Journal of Biochemistry &amp; Cell Biology, 41(7):1471–1481, July 2009. URL: http://dx.doi.org/10.1016/j.biocel.2009.01.016, doi:10.1016/j.biocel.2009.01.016. This article has 87 citations.](https://doi.org/10.1016/j.biocel.2009.01.016)

[9. (Brlek2023Case) Petar Brlek, Eduard Stjepan Pavelić, Jana Mešić, Kristijan Vrdoljak, Andrea Skelin, Šime Manola, Nikola Pavlović, Jasmina Ćatić, Gordana Matijević, Josep Brugada, and Dragan Primorac. Case report: state-of-the-art risk-modifying treatment of sudden cardiac death in an asymptomatic patient with a mutation in the scn5a gene and a review of the literature. Frontiers in Cardiovascular Medicine, September 2023. URL: http://dx.doi.org/10.3389/fcvm.2023.1193878, doi:10.3389/fcvm.2023.1193878. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcvm.2023.1193878)

[10. (Veerman2015The) Christiaan C. Veerman, Arthur A.M. Wilde, and Elisabeth M. Lodder. The cardiac sodium channel gene scn5a and its gene product nav1.5: role in physiology and pathophysiology. Gene, 573(2):177–187, December 2015. URL: http://dx.doi.org/10.1016/j.gene.2015.08.062, doi:10.1016/j.gene.2015.08.062. This article has 129 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2015.08.062)

[11. (Verkerk2018Disease) Arie O. Verkerk, Ahmad S. Amin, and Carol Ann Remme. Disease modifiers of inherited scn5a channelopathy. Frontiers in Cardiovascular Medicine, October 2018. URL: http://dx.doi.org/10.3389/fcvm.2018.00137, doi:10.3389/fcvm.2018.00137. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcvm.2018.00137)